The purpose of this protocol is to provide compassionate use of Kedrion Human Plasminogen Ophthalmologic Drops to an expanded population of patients diagnosed with ligneous conjunctivitis associated with type I Plasminogen deficiency until product licensure, and/or until a new clinical trial is available and the patients in treatment under Expanded Access are eligible to participate in the new trial.
Study Type
EXPANDED_ACCESS
Human Plasminogen
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.